Dose Equivalence of Remimazolam and Propofol for Loss of Consciousness in Pediatric Patients: A Randomized Clinical Trial.

IF 2.6 2区 医学 Q2 ANESTHESIOLOGY
Pain physician Pub Date : 2024-11-01
Yang Shen, Ying Sun, Yan-Ting Wang, Zhe-Zhe Peng, Jie Bai, Ji-Jian Zheng, Ma-Zhong Zhang
{"title":"Dose Equivalence of Remimazolam and Propofol for Loss of Consciousness in Pediatric Patients: A Randomized Clinical Trial.","authors":"Yang Shen, Ying Sun, Yan-Ting Wang, Zhe-Zhe Peng, Jie Bai, Ji-Jian Zheng, Ma-Zhong Zhang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Remimazolam and propofol can be used interchangeably for general anesthesia. However, no dosing recommendations exist for the intravenous bolus administration of remimazolam during general anesthesia induction in pediatric patients. Determining the appropriate dose for anesthesia induction in pediatric patients is crucial for safe and effective surgical procedures.</p><p><strong>Objectives: </strong>The study aimed to determine the median effective dose (ED50) for loss of consciousness (LOC) with remimazolam and propofol in pediatric patients and establish the dose equivalence between these anesthetics.</p><p><strong>Study design: </strong>A prospective, randomized, single-center trial.</p><p><strong>Setting: </strong>A tertiary pediatric hospital in China from January 2023 to July 2023.</p><p><strong>Methods: </strong>Pediatric patients aged 3 to 15 years, undergoing elective surgery under general anesthesia, were included. Patients were randomized to receive either remimazolam (in doses of 0.1, 0.15, 0.2, 0.25, and 0.3 mg/kg-1) or propofol (in doses of 0.75, 1.0, 1.25, and 1.5 mg/kg-1) via intravenous bolus. The primary measure consisted of determining the ED50 for LOC with remimazolam, and the secondary measure consisted of establishing the dose equivalence between remimazolam and propofol.</p><p><strong>Results: </strong>The calculated ED50 for remimazolam was 0.19 mg/kg-1 (95% CI: 0.10-0.35), and that for propofol was 1.11 mg/kg-1 (95% CI: 0.53-2.15). This finding indicates that remimazolam is approximately 5.8 times more potent than propofol.</p><p><strong>Limitations: </strong>In this study, the anesthesiologist could not be blinded to the different appearances of remimazolam and propofol, and the LOC assessment method may have introduced bias. Furthermore, the recommended dose for remimazolam induction was not tested directly within this trial, suggesting a need for further research.</p><p><strong>Conclusions: </strong>Remimazolam demonstrates significantly higher sedative efficacy for pediatric patients than does propofol. An induction dose of 0.34 mg/kg-1 remimazolam could be recommended for general anesthesia induction, considering the safety and effectiveness of a 2 mg/kg-1 dose of propofol.</p>","PeriodicalId":19841,"journal":{"name":"Pain physician","volume":"27 8","pages":"521-528"},"PeriodicalIF":2.6000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pain physician","FirstCategoryId":"3","ListUrlMain":"","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ANESTHESIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Remimazolam and propofol can be used interchangeably for general anesthesia. However, no dosing recommendations exist for the intravenous bolus administration of remimazolam during general anesthesia induction in pediatric patients. Determining the appropriate dose for anesthesia induction in pediatric patients is crucial for safe and effective surgical procedures.

Objectives: The study aimed to determine the median effective dose (ED50) for loss of consciousness (LOC) with remimazolam and propofol in pediatric patients and establish the dose equivalence between these anesthetics.

Study design: A prospective, randomized, single-center trial.

Setting: A tertiary pediatric hospital in China from January 2023 to July 2023.

Methods: Pediatric patients aged 3 to 15 years, undergoing elective surgery under general anesthesia, were included. Patients were randomized to receive either remimazolam (in doses of 0.1, 0.15, 0.2, 0.25, and 0.3 mg/kg-1) or propofol (in doses of 0.75, 1.0, 1.25, and 1.5 mg/kg-1) via intravenous bolus. The primary measure consisted of determining the ED50 for LOC with remimazolam, and the secondary measure consisted of establishing the dose equivalence between remimazolam and propofol.

Results: The calculated ED50 for remimazolam was 0.19 mg/kg-1 (95% CI: 0.10-0.35), and that for propofol was 1.11 mg/kg-1 (95% CI: 0.53-2.15). This finding indicates that remimazolam is approximately 5.8 times more potent than propofol.

Limitations: In this study, the anesthesiologist could not be blinded to the different appearances of remimazolam and propofol, and the LOC assessment method may have introduced bias. Furthermore, the recommended dose for remimazolam induction was not tested directly within this trial, suggesting a need for further research.

Conclusions: Remimazolam demonstrates significantly higher sedative efficacy for pediatric patients than does propofol. An induction dose of 0.34 mg/kg-1 remimazolam could be recommended for general anesthesia induction, considering the safety and effectiveness of a 2 mg/kg-1 dose of propofol.

雷马唑仑和异丙酚治疗儿童意识丧失的剂量等效:一项随机临床试验。
背景:雷马唑仑和异丙酚可在全身麻醉中交替使用。然而,对于小儿全麻诱导时静脉注射雷马唑仑的剂量尚无建议。确定儿科患者麻醉诱导的适当剂量对于安全有效的外科手术至关重要。目的:本研究旨在确定雷马唑仑和异丙酚治疗小儿患者意识丧失(LOC)的中位有效剂量(ED50),并建立这两种麻醉剂之间的剂量等效性。研究设计:前瞻性、随机、单中心试验。背景:2023年1月至2023年7月在中国一家三级儿科医院。方法:选取3 ~ 15岁在全身麻醉下进行择期手术的儿童患者。患者随机接受雷马唑仑(剂量为0.1、0.15、0.2、0.25和0.3 mg/kg-1)或异丙酚(剂量为0.75、1.0、1.25和1.5 mg/kg-1)静脉注射。主要测量方法是测定雷马唑仑治疗LOC的ED50,次要测量方法是建立雷马唑仑与异丙酚的剂量等效性。结果:计算雷马唑仑ED50为0.19 mg/kg-1 (95% CI: 0.10 ~ 0.35),异丙酚ED50为1.11 mg/kg-1 (95% CI: 0.53 ~ 2.15)。这一发现表明,雷马唑仑的效力大约是异丙酚的5.8倍。局限性:在本研究中,麻醉师无法对雷马唑仑和异丙酚的不同外观视而不见,LOC评估方法可能会引入偏倚。此外,本试验未直接测试雷马唑仑诱导的推荐剂量,这表明需要进一步研究。结论:雷马唑仑对小儿患者的镇静效果明显高于异丙酚。考虑到异丙酚2 mg/kg-1的安全性和有效性,推荐瑞马唑仑诱导剂量为0.34 mg/kg-1进行全身麻醉诱导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pain physician
Pain physician CLINICAL NEUROLOGY-CLINICAL NEUROLOGY
CiteScore
6.00
自引率
21.60%
发文量
234
期刊介绍: Pain Physician Journal is the official publication of the American Society of Interventional Pain Physicians (ASIPP). The open access journal is published 6 times a year. Pain Physician Journal is a peer-reviewed, multi-disciplinary, open access journal written by and directed to an audience of interventional pain physicians, clinicians and basic scientists with an interest in interventional pain management and pain medicine. Pain Physician Journal presents the latest studies, research, and information vital to those in the emerging specialty of interventional pain management – and critical to the people they serve.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信